Rapport Therapeutics, Inc. Common Stock (RAPP) — Financial Flexibility Index

Latest as of March 2026: -0.50x

Rapport Therapeutics, Inc. Common Stock (RAPP) has a Financial Flexibility Index of -0.50x as of March 2026. Free cash flow of $-12.97 Million (operating CF $-13.06 Million minus capex $86.00K) represents 0% of total liabilities ($26.09 Million). Also explore Rapport Therapeutics, Inc. Common Stock annual equity growth to track the company's year-over-year net asset growth rate.

Financial Flexibility Index

-0.50x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-12.97 Million
Operating CF − Capex

Total Liabilities

$26.09 Million
USD

Capital Expenditures

$86.00K
USD

Rapport Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)

Historical Financial Flexibility Index trend for Rapport Therapeutics, Inc. Common Stock across 4 annual periods. Check Rapport Therapeutics, Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Annual Financial Flexibility Index for Rapport Therapeutics, Inc. Common Stock (2022–2025)

Year-by-year free cash flow to debt coverage for Rapport Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see Rapport Therapeutics, Inc. Common Stock stock valuation.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2025 -3.13x $-86.86 Million $-87.47 Million $27.78 Million ▲ +52.4%
2024 -6.57x $-62.42 Million $-64.83 Million $9.51 Million ▼ -4554.3%
2023 -0.14x $-25.55 Million $-27.18 Million $181.06 Million ▲ +42.3%
2022 -0.24x $-2.96 Million $-3.24 Million $12.10 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities